ToeFX selected for the OBIO-CAAP 2021 cohort

ToeFX product - feet on beach

On June 3, 2021, ToeFX Inc., a Hamilton-based healthtech startup and The Forge alumnus, announced that it has been selected for the 2021 Capital Access Advisory Program from The Ontario Bioscience Innovation Organization (OBIO®). OBIO CAAP operates downstream from existing entrepreneurship programs and focuses on accelerating technology commercialization, post-seed financing, and strategic partnerships. The program is in its ninth year and has selected eight startups to join OBIO CAAP cohort. The startups will work with OBIO and their expert advisor network over the next year to achieve key goals and objectives that will position them for successful financing.

OBIO CAAP creates high-value deal flow for both companies and investors, culminating with a presentation at the OBIO Investment Summit at which presenting companies have raised over $700M since 2018.

“ToeFX is proud to be recognized as a high potential health science company and looking forward to continuing the momentum with many more innovative solutions,” said Dr. Monica Yazdanian, CEO and co-founder of ToeFX Inc.

Read more about ToeFX on their website (toefx.com).